Research ID
hum0030-v5Release info
Latest
Research title
The Molecular Biological Analysis about Occurrence and Malignant Transformation in gynecological carcinogenesis
Research overview
- Aims
- To clarify the biological difference between clear cell carcinoma and other histological subtypes in ovarian carcinomas by comparing copy number variants, and to identify molecular subtypes and carcinogenesis in clear cell ovarian carcinomas by whole-exome sequencing and RNA-sequencing. Then, characterize high-grade serous carcinomas by NGS-based, integrative genomic analyses, with focus on homologous recombination deficiency, molecular subtypes, and prognostic factors and effectiveness of PARP inhibitor. Based on the results of whole-exome sequencing, an investigator-initiated, phase 2 clinical trial will be conducted to evaluate the efficacy and safety of the PARP inhibitor olaparib in HRD-positive cases.
Understanding the immune regulatory mechanisms in endometrial cancer is crucial for improving immunotherapy strategies. To elucidate the relationship between the tumor immune microenvironment and HLA class I expression, with a particular focus on their impact on CD8+ T cell infiltration patterns. By investigating the molecular basis of immune evasion across different histological and molecular subtypes, we will generate evidence that will contribute to the development of personalized immunotherapy strategies. - Methods
- Copy Number Variation Analysis: Gene Chip Human Mapping 250K Nsp Arrays were used for detecting the signal intensity of about 260 thousands SNPs and intensities of ovarian clear cell carcinoma were compared to the ones of non-carcinoma.
Whole Exome sequencing and RNA-seq
Methylation array and Expression array
Target bisulfite sequencing - Participants/materials
- Ovarian cancer: 57 cases (12 endometrioid carcinoma) + 111 cases + 31 + 189 cases, Endometrial cancer: 86 cases
- URL
- N/A
Datasets
| Cart | Dataset ID | Type of data | Analysis method | Access criteria | Date published |
|---|---|---|---|---|---|
| JGAD000022 | Copy Number Variations in cancer genome |
| Controlled-access (Type I) | 2020-09-28 | |
| JGAD000682 | NGS (Exome, RNA-seq) |
| Controlled-access (Type I) | 2024-05-13 | |
| JGAD000931 | NGS (Exome) |
| Controlled-access (Type I) | 2025-07-09 | |
| JGAD001041 | NGS (Target bisulfite-seq) |
| Controlled-access (Type I) | 2026-04-22 |
Data provider
- Principal investigator
- Katsutoshi Oda
- Affiliation
- Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo
Research projects
No research projects.
Grants
| Name | Title | Project number |
|---|---|---|
KAKENHI Grant-in-Aid for Scientific Research (S) | An Integrated Genomic Analysis on Evolution of Cancer Cell Population |
|
KAKENHI Grant-in-Aid for Scientific Research (C) | Search for the New Molecular Targeted Therapies and Biomarkers Inducing Apoptosis in Endometrial Carcinoma and Ovarian Carcinoma |
|
KAKENHI Grant-in-Aid for Young Scientists (B) | Search for the New Molecular Targeted Therapies Based on Genetic Profiles of Ovarian Clear Cell Carcinoma |
|
Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT) | Development of the Intractable Cancer Therapies through the New Target Identification by the Molecular Profiling (The Identification of the Gene Variation to Regulate the Treatment Sensitivity of the Progressive Ovarian Cancer) |
|
KAKENHI Grant-in-Aid for Young Scientists (B) | Carcinogenesis and Disorder of SWI/SNF Chromatin Remodeling Complex in Ovarian Clear Cell Carcinoma |
|
KAKENHI Grant-in-Aid for Scientific Research (C) | Investigation of Novel Molecularly Targeted Therapies Focusing on Homologous Recombination Repair Defeciency in Ovarian Cancer |
|
KAKENHI Grant-in-Aid for Scientific Research (B) | Clinical utility of genetic analysis and organoid-based drug sensitivity testing in ovarian cancer. |
|
KAKENHI Grant-in-Aid for Scientific Research (B) | Development of a Drug-Sensitive Methylation Diagnostic Kit and Application to Liquid Biopsy for Ovarian/Uterine Cancer |
|
Related publications
| Title | DOI | Dataset ID |
|---|---|---|
Integrated Copy Number and Expression Analysis Identifies Profiles of Whole-Arm Chromosomal Alterations and Subgroups with Favorable Outcome in Ovarian Clear Cell Carcinomas | ||
The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinoma | ||
Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma | ||
Integrated genomic/epigenomic analysis stratifies subtypes of clear cell ovarian carcinoma, highlighting their cellular origin | ||
HLA class I dysregulation and immune microenvironment across endometrial cancer molecular subtypes | N/A |
Controlled access users
| Principal investigator | Affiliation | Country/Region | Research title | Period of data use | Dataset ID |
|---|---|---|---|---|---|
| Ikuo Konishi | Department of Gynecology and Obstetrics, Kyoto University | Japan | Integrated analyses of omics (genomics, transcriptomics, proteomics and metabolomics) associated with clinical variables for developing indivisualized treatment in gynecologycal malignancy | 2015-07-03 – 2017-09-04 | |
| Masaki Mandai | department of Gynecology and Obstetrics, Kyoto University Faculty of Medicene | Japan | Integrated analyses of omics (genomics, transcriptomics, proteomics and metabolomics) associated with clinical variables for developing indivisualizedtreatment in gynecological malignancy | 2018-10-04 – 2025-04-14 | |
| Noriomi Matsumura | Obstetrics and Gynecology, Kindai University | Japan | Integrated multi-omics analysis for ovarian clear cell adenocarcinoma: JGOG3017-TR1 | 2024-10-15 – 2027-12-31 | |
| Ken Yamaguchi | Gynecology and Obstetrics, Kyoto University | Japan | Integrated multi-omics analysis for ovarian clear cell adenocarcinoma: JGOG3017-TR1 | 2024-10-22 – 2027-12-31 |